Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Don't forget Aug. 2024: " This open label, rand

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155378
(Total Views: 432)
Posted On: 11/04/2024 6:58:36 PM
Posted By: My69z
Don't forget Aug. 2024:

" This open label, randomized (1:1), multicenter trial will evaluate the anti-tumor activity (via overall response rate, ORR) of leronlimab at doses of 350 mg and 700 mg in combination TAS-102 and bevacizumab in approximately 60 patients with CCR5+, microsatellite stable metastatic CRC (mCRC)."
___

Ai excerpt:

Bevacizumab, also known as Avastin, is a targeted cancer drug treatment that's used in combination with chemotherapy or as a single agent to treat a variety of cancers:

Solid tumors
Bevacizumab is approved in 134 countries to treat many types of solid tumors, including breast, colorectal, lung, ovarian, renal cell, and cervical cancer.

Glioblastoma
Bevacizumab is approved to treat progressive glioblastoma after previous therapy.

Metastatic renal cell carcinoma
Bevacizumab is approved to treat metastatic renal cell carcinoma in combination with interferon alfa.

Bevacizumab is an anti-angiogenic therapy that prevents the growth of new blood vessels. It's administered intravenously as a clear, colorless solution in doses of 5, 7.5, 10, or 15 mg/kg.
___

134 countries & a laundry list of cancers.

This is going to be extremely significant for LL.

On our August news, MGK & others pointed the potential turn-around time to data read-out on ORR can be a very fairly quick timeline.

If I remember right, others also mentioned great ORR results can basis Cytodyn filing for early, Conditional Approval.

I think that potential is particularly why the FDA relationship is reinforced.

An optic message to shareholders of --- think to the near & distant future(s).

Because now Leronlimab's got this.


(5)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us